The Overuse of SABA inhalers in Primary Care
Recent data has shown a pattern of excess reliance on short acting beta agonist (SABA) inhalers. The impact is not only potential health risks it also has financial implications. It also highlights the need for proactive treatment and patient education surrounding respiratory conditions.
If you would like to see our practice level data, please contact our team at licb.mo@nhs.net.